论文部分内容阅读
非小细胞肺癌(NSCLC)属于临床常见疾病,随着对其临床研究增多,近几年逐渐在NSCLC中发现一种新型致癌基因,即棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶(EML4-ALK),其参与非小细胞肺癌发生与发展过程。针对该发现,一些学者提出可利用EML4-ALK作为靶点研究相关的抑制剂治疗非小细胞肺癌,而且在临床中也逐渐应用起来,显示EML4-ALK抑制剂在非小细胞肺癌中有不错的效果。但是,随着应用增多,耐药问题也逐渐增多,为了进一步探讨EML4-ALK抑制剂在非小细胞肺癌中的耐药机制,本文进行了综述。
Non-small cell lung cancer (NSCLC) is a common clinical disease. With the increase of clinical research, NSCLC has gradually found a new oncogene in NSCLC in recent years, namely echinoderm-like protein-like 4-anaplastic lymphoma kinase EML4-ALK), which is involved in the occurrence and development of non-small cell lung cancer. In response to this finding, some scholars have suggested that EML4-ALK can be used as a target-related inhibitor in the treatment of non-small cell lung cancer, and it has gradually been applied clinically to show that EML4-ALK inhibitors have good non-small cell lung cancer effect. However, with the increase of application, the problem of drug resistance also gradually increases. In order to further explore the mechanism of drug resistance of EML4-ALK inhibitor in non-small cell lung cancer, this article reviews.